Literature DB >> 26961677

Peripherally Inserted Central Venous Catheter Complications in Children Receiving Outpatient Parenteral Antibiotic Therapy (OPAT).

Amanda Kovacich1, Pranita D Tamma2, Sonali Advani3, Victor O Popoola2, Elizabeth Colantuoni4, Leslie Gosey5, Aaron M Milstone6.   

Abstract

OBJECTIVE To identify the frequency of and risk factors associated with complications necessitating removal of the peripherally inserted central catheters (PICCs) in patients receiving outpatient parenteral antibiotic therapy (OPAT) and to determine the appropriateness of OPAT in children with OPAT-related complications. METHODS A retrospective cohort of children who had a PICC inserted at the Johns Hopkins Children's Center between January 1, 2003, and December 31, 2013, and were discharged from the hospital on OPAT was assembled. RESULTS A total of 1,465 PICCs were used to provide antibiotic therapy for 955 children after hospital discharge. Among these, 117 PICCs (8%) required removal due to a complication (4.6 of 1,000 catheter days). Children discharged to a long-term care facility were at increased risk of adverse PICC events (incidence risk ratio [IRR], 3.32; 95% confidence interval [CI], 1.79-6.17). For children receiving OPAT, age of the child (adjusted IRR [aIRR], 0.95; 95% CI, 0.92-0.98), noncentral PICC tip location (aIRR, 2.82; 95% CI, 1.66-4.82), and public insurance (aIRR, 1.63; 95% CI, 1.10-2.40) were associated with adverse PICC events. In addition, 34 patients (32%) with adverse events may not have required intravenous antibiotics at the time of hospital discharge. CONCLUSIONS Of children discharged with PICCs on OPAT during the study period, 8% developed a complication necessitating PICC removal. Children discharged to a long-term care facility had an increased rate of complication compared with children who were discharged home. With improved education regarding appropriate duration of antibiotic therapy and situations in which early conversion to enteral therapy should be considered, PICC-related complications may have been avoided in 32% of children. Infect.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26961677     DOI: 10.1017/ice.2015.317

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  6 in total

1.  Optimizing the Management of Uncomplicated Gram-Negative Bloodstream Infections in Children: Translating Evidence From Adults Into Pediatric Practice.

Authors:  Rebecca G Same; Alice J Hsu; Pranita D Tamma
Journal:  J Pediatric Infect Dis Soc       Date:  2019-11-06       Impact factor: 3.164

2.  Economic Burden of Home Antimicrobial Therapy: OPAT Versus Oral Therapy.

Authors:  Nathan M Krah; Tyler Bardsley; Richard Nelson; Lawanda Esquibel; Mark Crosby; Carrie L Byington; Andrew T Pavia; Adam L Hersh
Journal:  Hosp Pediatr       Date:  2019-04

3.  Complications with peripherally inserted central catheters (PICCs) used in hospitalized patients and outpatients: a prospective cohort study.

Authors:  Delphine Grau; Béatrice Clarivet; Anne Lotthé; Sébastien Bommart; Sylvie Parer
Journal:  Antimicrob Resist Infect Control       Date:  2017-01-28       Impact factor: 4.887

4.  Excellent Outcomes With the Selective Use of Oral Antibiotic Therapy for Bone and Joint Infections: A Single-Center Experience.

Authors:  Mason A Halouska; Zachary A Van Roy; Amanda N Lang; Jacey Hilbers; Angela L Hewlett; Nicolas W Cortes-Penfield
Journal:  Cureus       Date:  2022-07-18

Review 5.  Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK.

Authors:  Ann L N Chapman; Sanjay Patel; Carolyne Horner; Helen Green; Achyut Guleri; Sara Hedderwick; Susan Snape; Julie Statham; Elizabeth Wilson; Mark Gilchrist; R Andrew Seaton
Journal:  JAC Antimicrob Resist       Date:  2019-08-26

6.  Adult 'PICC' Device May be Used as a Tunnelled Central Venous Catheter in Children.

Authors:  Brooke T Lawson; Ian A Zealley
Journal:  Cardiovasc Intervent Radiol       Date:  2018-01-17       Impact factor: 2.740

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.